PD-1/PD-L1 inhibitors treatment in lung cance | EurekAlert!
PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome. - Abstract - Europe PMC
Frontiers | Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer | Oncology
Mechanism of action of PD-1 and PD-L1 inhibitors. The programmed cell... | Download Scientific Diagram
Revisiting the PD-1 pathway
Mechanistic insight of predictive biomarkers for antitumor PD‑1/PD‑L1 blockade: A paradigm shift towards immunome evaluation (Review)
Recent advance of peptide-based molecules and nonpeptidic small-molecules modulating PD-1/PD-L1 protein-protein interaction or targeting PD-L1 protein degradation - ScienceDirect
JCI - A tumor-intrinsic PD-L1/NLRP3 inflammasome signaling pathway drives resistance to anti–PD-1 immunotherapy
Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives - Cancer Treatment Reviews
Definition of immune checkpoint inhibitor - NCI Dictionary of Cancer Terms - National Cancer Institute
Cancers | Free Full-Text | Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors
Frontiers | Looking for the Optimal PD-1/PD-L1 Inhibitor in Cancer Treatment: A Comparison in Basic Structure, Function, and Clinical Practice | Immunology
Frontiers | PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake | Pharmacology
Mechanism of action of PD-1 and PD-L1 inhibitors. Tumor cells develop... | Download Scientific Diagram
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy | Molecular Cancer | Full Text
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therap | DDDT
Ezabenlimab | Investigational Compounds | InOncology
Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action | Immunotherapy
IJMS | Free Full-Text | Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection | HTML
Mechanism of action of PD‐1 receptor/ligand targeted cancer immunotherapy - Borst - 2021 - European Journal of Immunology - Wiley Online Library
Mechanism of action of immune checkpoint inhibitors. PD-1 is... | Download Scientific Diagram
Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway | Acta Pharmacologica Sinica
Nivolumab: targeting PD-1 to bolster antitumor immunity | Future Oncology
Release the B7.1! Anti-PD-L1 breaks PD-L1's grip
Immune-related adverse events of checkpoint inhibitors | Nature Reviews Disease Primers
Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer - ScienceDirect
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics | Journal of Hematology & Oncology | Full Text
